A growing number of Eliquis lawsuits continue to be filed in federal courts nationwide, alleging that Bristol -Myers Squibb and Pfizer Inc. failed to disclose the risk of bleeding problems associated with their new generation anticoagulant. If you or a loved one has suffered gastrointestinal bleeding, bleeding of other internal organs, cerebrovascular bleeding or a stroke after taking Eliquis, contact us online or call immediately at 1-866-252-3535.
UPDATE: The ISMP QuarterWatch published on September 23, 2015 includes an examination of the safety profiles of Eliquis, one of the new “novel” oral anticoagulants. In drawing on FDA data from the second half of 2014, the ISMP (“Institute for Safe Medication Practices”) opined:
As previously noted in this publication, bringing a new generation of oral anticoagulants to market based on ease of use rather than improved safety was a major wrong turn.
UPDATE: In July 2015, Bloomberg reported the FDA delayed approving Eliquis for nine months after finding evidence of major fraud and other problems at a Chinese clinical trial site. Documents show that one death went unreported, other “serious adverse events” were concealed, and records were changed or went missing just before the FDA arrived to inspect the trial site in Shanghai — reportedly on the order of a Chinese-based employee of Bristol-Myers Squibb (Wall Street Journal).
Eliquis is in the same family of anticoagulants as Pradaxa and Xeralto. Originally approved in 2012 for stroke prevention in patients who suffer from atrial fibrillation, its use was later expanded to patients at risk for pulmonary embolism (PE) and deep vein thrombosis (DVT), conditions also caused by blood clots. These medications were widely proclaimed to be far superior to the previous go-to blood thinner, warfarin (Coumadin) because they were claimed to require less patient blood monitoring and fewer dietary restrictions. The truth is that Eliquis, warfarin, and all anticoagulants are designed to reduce the likelihood of dangerous blood clots. However, what Pfizer and Bristol-Myers Squibb, the makers of Eliquis, don’t want you to know is there is no reversal agent for Eliquis internal bleeding, which may be fatal. When a patient develops internal bleeding or a hemorrhage while taking warfarin, the bleed can be stopped with a dose of Vitamin K. When it happens to a patient taking Eliquis, it is often uncontrollable, increasing the risk of serious injury or death.
Although Eliquis may allow patients to make fewer doctor visits than older anticoagulants, many agree with the authors of a study published in the Journal of Neurosurgery in August 2014: “Despite their convenience, efficacy and lower (brain bleed) risk, a major limitation of the targeted OACs (oral anticoagulants i.e. Eliquis) is that there is currently no specific antidote for any of the agents.”
If you or a loved one has suffered gastrointestinal bleeding, bleeding of other internal organs, cerebrovascular bleeding or a stroke after taking Eliquis, contact us online or call immediately at 1-866-252-3535.